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We have studied the abilities of different transactivation domains to stimulate the initiation and elongation
(postinitiation) steps of RNA polymerase II transcription in vivo. Nuclear run-on and RNase protection
analyses revealed three classes of activation domains: Sp1 and CTF stimulated initiation (type I); human
immunodeﬁciency virus type 1 Tat fused to a DNA binding domain stimulated predominantly elongation (type
IIA); and VP16, p53, and E2F1 stimulated both initiation and elongation (type IIB). A quadruple point
mutation of VP16 converted it from a type IIB to a type I activator. Type I and type IIA activators synergized
with one another but not with type IIB activators. This observation implies that synergy can result from the
concerted action of factors stimulating two different steps in transcription: initiation and elongation. The
functional differences between activators may be explained by the different contacts they make with general
transcription factors. In support of this idea, we found a correlation between the abilities of activators,
including Tat, to stimulate elongation and their abilities to bind TFIIH.
Stimulation of eukaryotic gene expression requires se-
quence-speciﬁc factors with DNA binding domains and acti-
vation domains that interact with the general transcription
factors (GTFs) and recruit RNA polymerase II (pol II) to the
promoter (3, 65). In vivo the transcriptionally active form of
pol II is probably a holoenzyme complex which contains a
number of the GTFs as well as other polypeptides (36). Dif-
ferent activation domains interact with different GTFs, includ-
ing TFIIB (44), TFIID (17, 19, 63), and TFIIF (76). These
interactions are thought to recruit, stabilize, and/or modify the
activity of the pol II holoenzyme.
We recently demonstrated that the activation domains of
p53, VP16, and E2F1 bind directly to TFIIH (50a, 72). TFIIH
is a multisubunit factor, different forms of which are required
for both transcription and nucleotide excision repair of DNA
(9). TFIIH is the only GTF which has enzymatic activities: it
has two helicase subunits and a cyclin-dependent protein ki-
nase subunit which phosphorylates the pol II large-subunit
C-terminal domain (CTD) (12, 52, 58, 60). Both of these en-
zymatic activities are implicated in steps in transcription which
occur shortly after initiation of the RNA chain. First, a helicase
is required for efﬁcient formation of open complexes and for
promoter clearance on linear templates in vitro (20). Second,
when paused polymerases resume elongation on several Dro-
sophila genes in vivo, the CTD becomes phosphorylated, sug-
gesting a possible role for TFIIH kinase in regulating elonga-
tion (50, 70). Furthermore, inhibitors of the TFIIH kinase
inhibit elongation under activated (74), but not basal (57),
transcription conditions.
In vivo, rate-limiting steps after initiation have been well
documented for a number of genes. For example, polymerases
stall 20 to 40 bases downstream of the start sites in the Dro-
sophila hsp70 and human c-myc genes (38, 51, 64) and termi-
nate prematurely in the human immunodeﬁciency virus (HIV)
provirus (31, 34). Promoter-proximal pausing appears to be a
general phenomenon, not restricted to a small subset of pro-
moters (37). It is not clear how promoter-proximal pausing and
premature termination of transcription in vivo relate to pro-
moter clearance in vitro because no speciﬁc assay for promoter
clearance has been developed in vivo. In this paper, we there-
fore use the term elongation in its broadest sense to refer to all
nucleotide addition steps after initiation.
Certain activators, including HIV Tat and the Gal4-VP16
fusion protein, stimulate elongation by pol II (1, 21). Because
rate-limiting steps after initiation appear to be widespread in
vivo, the abilities of activators to affect elongation are of great
potential importance to the control of gene expression. Stim-
ulation of elongation, like that of initiation, may involve con-
tacts between activation domains and GTFs. Squelching by
excess VP16 in trans inhibited elongation, suggesting that this
activation domain can sequester a factor(s) required for efﬁ-
cient elongation (73).
It is not known if Tat and VP16 stimulate elongation by
similar mechanisms. Tat is able to stimulate elongation, in
some cases without any apparent effect on initiation (31, 33, 40,
47), whereas VP16 also strongly stimulates initiation. Tat is a
unique activator because it is recruited to the transcription
complex by binding to nascent RNA rather than to promoter
DNA. Although Tat can activate transcription when tethered
to DNA (2, 29, 62), it is not known whether, under these
circumstances, it affects elongation or initiation.
The binding of two or more activators to a single template
often causes more-than-additive stimulation of transcription, a
phenomenon called synergy. Multiple copies of a single acti-
vator, as well as two different activators, can synergize (4, 43).
For example, Tat synergizes with Sp1, but not with VP16 (29,
62). In many cases, it is not known why some combinations
synergize while others do not. Three mechanisms of transcrip-
tional synergism have been identiﬁed: (i) cooperative DNA
binding (18), (ii) formation of multiple contacts between acti-
vators and GTFs (4, 6, 42), and (iii) derepression of chromatin
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2044templates by displacement of nucleosomes (5). It has also been
suggested that synergy could result from the stimulation of
different rate-limiting steps in transcription (25).
In this study, we have surveyed a number of cellular and viral
activation domains for their abilities to stimulate postinitiation
steps in transcription. We show that a subset of cellular acti-
vation domains have the ability to stimulate elongation, while
others stimulate only initiation. Only those activators which do
not stimulate elongation synergize with HIV Tat. We show that
a mutant of the VP16 activation domain uncouples the stimu-
lation of elongation from that of initiation. Furthermore, we
have found a correlation between those activators that stimu-
late elongation and those that bind to TFIIH.
MATERIALS AND METHODS
Plasmids. Expression vectors for Gal4 fusion proteins were derived from
pSG424 (55). Gal4(1-94) was expressed from pSG1-94, made by deleting se-
quences downstream of the HpaI site in pSGVPD490 (54). Gal4(1-147) was ex-
pressed from pSG1-147 (73). Gal4-VP16(410-490) was expressed from pSGVPD
490. Gal4-SW6 was expressed from pSGSW6 in which the XhoI-StyI fragment
of SW6 (68) was inserted into pSGVPD490. Gal4-Tat(1-48) was expressed
from pHKGTat1-48, made by inserting the XhoI-EcoNI fragment of Gal4-Tat
(62) into pHKG4 (22). Gal4-Sp1B(263-499) was expressed from pHKGSp1
(516D112), a gift of B. Khoo and S. Jackson. Gal4-E2F1(380-437) was expressed
from pHKGE2F(380-437) (22). Gal4-CTF(399-499) was expressed from pH-
KGCTF(399-499), a gift of B. Khoo and S. Jackson. Gal4-p53(1-92) was ex-
pressed from pGalMp53(1-92) (46).
pSp65-VA1 (48) contains the adenovirus type 2 VA1 gene. pGal5-HIV2 CAT
has been described previously (73). pGal1-HIV2 CAT was made by inserting the
XbaI-NcoI HIV2-CAT fragment from pGal5-HIV2 CAT into Gal1 E1b CAT
(22). pGal5-c-myc P2 luciferase was constructed by inserting the PvuII-SacI
fragment of pGal5-P2 CAT (73) into the SmaI-SacI sites of pGL2 (Promega).
pGal5-Sp4-HIV2 CAT was constructed from pGal5-HIV2 CAT (73) by insertion
of an oligonucleotide [(GGGGCGGGAC)4] into the XbaI site. pGal5-Sp4-E1b
CAT was constructed by inserting the same oligonucleotide into the XbaI site of
pGal5-E1b CAT (Gal4/E1bTATA) (41).
pGX-3X-Tat was constructed by inserting a Tat gene that was PCR ampliﬁed
from ptat72 (14) into the BamHI site of pGEX-3X. pGX-3X-Tat1-48 was con-
structed by digesting pGX-3X-Tat with EagI and EcoRI, ﬁlling in, and recircu-
larizing.
The GST-Sp1A and GST-Sp1B expression plasmids were described previously
(11). GST-CTF was expressed from pGEX20T-CTF, which contains residues 399
to 499 of CTF. GST-VP16 was expressed from pGEX2T-VP16, made by insert-
ing the EcoRI fragment from pSGVPD490 (54) encoding residues 410 to 490 of
VP16. GST-SW6 was constructed by insertion of the SphI-StyI fragment of pSW6
(68) into the pGEX2T-VP16 plasmid.
Transfection, chloramphenicol acetyltransferase (CAT) assay, nuclear run-on
reaction, and RNase protection. 293 cells were transiently transfected with cal-
cium phosphate precipitates. HeLa cells were transfected with DEAE-dextran
and then treated with dimethyl sulfoxide and chloroquine. All cells were har-
vested after 40 h. For Fig. 2, 293 cells on 15-cm-diameter plates were transfected
with 24 mg of pGal5-c-myc P2 luciferase, 200 ng of RSV-CAT, and 4 mgo f
various Gal4 expression plasmids. For Fig. 3, 4, and 5, 293 cells were transfected
with 10 mg of pGal5-HIV2 CAT, 1 mg of pSp65-VA1, 200 ng of RSV-luciferase,
and 2 mg of various Gal4 expression plasmids. For Fig. 3, 4, and 5, 293 cells were
transfected with 10 mg of pGal5-HIV2 CAT, 1 mg of pSp65-VA1, 200 ng of
RSV-luciferase, and 2 mg of various Gal4 expression plasmids. For Fig. 6 and 7,
HeLa cells were transfected with 8 mg of pGal5-HIV2 CAT, 1.5 mg of Gal4
expression plasmid, 1 mg of RSV-luciferase, 1.5 mg of pSV-HIV1-tat (10) or
empty PECE vector, and 1 mg of pSp65-VA1 (Fig. 7). For Fig. 8 and 9, 293 cells
were transfected with 5 mg of reporter, 100 ng of RSV-luciferase, 1 mg of various
Gal4 expression plasmids, and 0.5 mg of pSp65-VA1 (Fig. 9).
RNA isolation (which includes a DNase step) and RNase protection assays
were as described previously (26, 73). All RNase protection experiments shown
were repeated at least twice in independent transfections. For quantitation of
RNase protection, autoradiographs were scanned by densitometry and the areas
under the curves were integrated. Correction factors for the difference in radio-
active U content between the read-through (RT) band and the shorter termi-
nated (TM) bands were 1.67 and 5 for the longer and shorter TM bands,
respectively.
Nuclear run-on reactions were carried out in a ﬁnal concentration of 105 mM
potassium glutamate as previously described (73) except that the extension
reaction was reduced from 10 to 1 min. M13 probes for HIV type 2 (HIV-2) TAR
and mouse c-myc sequences have been described previously (73). Luciferase
probes 4 and 5 in Fig. 2 are M13 clones of the EcoRI-TaqI and EcoRV-BstYI
fragments. The upstream probe G is the PstI-BamHI fragment containing ﬁve
Gal4 binding sites from Gal4/E1bTATA (41) cloned into M13mp18. The CAT
probes 2 and 3 in Fig. 3 contain the HindIII-PvuII and EcoRI-ScaI fragments,
respectively, in M13.
CAT assays utilized the
14C-labeled acetyl coenzyme A substrate, and quan-
tiﬁcation was by scintillation counting. Each sample was assayed in duplicate.
Protein-protein interaction assays. For Fig. 10A, 800-ml aliquots of HeLa
whole-cell extracts (61) were chromatographed on afﬁnity columns (40 ml) con-
taining 4 mg of glutathione S-transferase (GST) or GST fusion protein per ml,
except for GST-Sp1A and GST-Sp1B, which were immobilized at 6 mg/ml.
Bound proteins were eluted with 160 ml of 1 M NaCl in ACB buffer (72) and
subsequently with 160 ml of 1% sodium dodecyl sulfate (SDS) (72).
For Fig. 10B, 10-mg samples of HeLa nuclear extracts in buffer D (59) with 50
mM KCl were loaded onto 0.6-ml columns containing immobilized GST proteins
at 1 mg/ml. Proteins were eluted with buffer D supplemented with 0.6 M KCl.
Eluted samples (20 ml) were immunoblotted with anti-p62 monoclonal anti-
body 3c9 (13) or anti-MO15 antibody 2F8 (52) and visualized by enhanced
chemiluminescence (ECL; Amersham).
RESULTS
Activators differ in their abilities to stimulate elongation:
nuclear run-on analysis. We measured the abilities of different
activation domains to stimulate transcriptional elongation by
using the nuclear run-on assay. Fusions of various activation
domains with the DNA binding domain of Saccharomyces cer-
evisiae Gal4 (amino acids 1 to 147) (Fig. 1) were coexpressed in
transiently transfected 293 cells with the pGal5-c-myc P2 lucif-
erase reporter plasmid (see Fig. 2). After 40 h, nuclei were
harvested and allowed to continue transcription in the pres-
ence of [a-
32P]UTP. RNA was isolated and hybridized to a
series of ﬁve single-stranded M13 probes spanning the length
of the reporter plasmid. The intensity of the signal on each
probe gives a measure of the relative polymerase density on
that region of the gene at the time the nuclei were isolated.
This assay therefore gives a ‘‘snapshot’’ view of the distribution
of polymerases along the gene averaged over the population of
cells in the culture. If polymerases are distributed evenly along
the length of the gene, we infer that elongation is efﬁcient. If,
on the other hand, a higher polymerase density is observed at
the 59 end than at the 39 end, we infer that elongation is
inefﬁcient and that polymerases are stalling or terminating
prematurely. Our run-on conditions (105 mM K
1 glutamate)
FIG. 1. Gal4 fusion proteins used as activators in this study.
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run-on signal reﬂects both stalled and actively elongating poly-
merases, it is not an accurate measure of initiation rate but
only of the density of preinitiated polymerases (see Discus-
sion). To control for upstream initiation and transcription
which reads all the way around the plasmid, in some experi-
ments we included a probe, G, which is located upstream of the
c-myc start site. In all cases the amount of read-around tran-
scription detected by this probe was low relative to that which
is correctly initiated (see Fig. 2 to 4).
Our results revealed two classes of activation domains: those
that stimulate transcription by polymerases which elongate ef-
ﬁciently and those that stimulate transcription by polymerases
which elongate poorly. So that elongation efﬁciencies can eas-
ily be compared, the autoradiographs in Fig. 2 were exposed to
give approximately equal signals for the 59 end (probe 1), and
polymerase densities were plotted relative to the density at the
59 end. After correction for transfection efﬁciency, the relative
59 polymerase densities were approximately 1, 10, 1, 2, and 2
for Gal4-(1-147), -VP16, -Tat(1-48), -Sp1, and -SW6, respec-
tively. In agreement with previous results (73), transcription in
the absence of an activation domain [Gal4(1-147)] showed a
decline in polymerase density between the 59 and 39 ends of the
gene, implying that, under these conditions, transcripts were
elongated poorly (Fig. 2). In contrast, transcription activated
by Gal4-VP16 had equivalently high polymerase densities at
the 59 and 39 ends of the gene, suggesting that this activator
stimulates elongation, as previously shown (73).
Gal4-Tat(1-48) contains the activation domain of Tat but
not its arginine-rich RNA binding domain (amino acids 49 to
74); it does not bind TAR RNA and cannot activate transcrip-
tion from the HIV-2 long terminal repeat (2a). Gal4-Tat(1-48),
like Gal4-VP16, stimulated elongation efﬁciency relative to
Gal4(1-147), although it is a 100-fold-weaker activator than
Gal4-VP16 as measured by luciferase expression (Fig. 2). We
conclude that stimulation of elongation by a transactivator is
not necessarily correlated with a high level of initiation.
Gal4-Sp1, like Gal4-Tat(1-48), is a weak activator (8), but in
contrast to Gal4-Tat(1-48), it gave rise to a pattern of tran-
scription with a higher polymerase density at the 59 end of the
gene than at the 39 end (Fig. 2). This observation shows that
Gal4-Sp1 activates transcription complexes with low processiv-
ity which tend to stall and/or fall off shortly after initiation, in
agreement with two recent reports (37, 75).
We also examined transcription stimulated by a mutant
VP16 activation domain by using Gal4-SW6 (68), which has
FIG. 2. Activators differ in their abilities to stimulate elongation. Nuclear run-on analysis of pGal5-c-myc P2 luciferase transiently transfected into 293 cells with
Gal4(1-147), -VP16, -Tat(1-48), -Sp1, or -SW6 (VP16 mutant) is shown. Autoradiograms were exposed for 7 days, 6 h, 7 days, 24 h, and 48 h, respectively. Polymerase
densities were calculated from PhosphorImager data corrected for U content (see map). After correction for transfection efﬁciency, the relative 59 (probe 1) polymerase
densities were approximately 1, 10, 1, 2, and 2 for Gal4(1-147), -VP16, -Tat(1-48), -Sp1, and -SW6, respectively. In the graphs, polymerase density was normalized to
1.0 for probe 1 and plotted versus distance from the start site to the center of each probe. The upstream probe G is shown for Gal4(1-147), -VP16, and -Sp1. Luciferase
activity is expressed relative to that for Gal4(1-147) and normalized to CAT activity from for cotransfected RSV-CAT. 53GAL, ﬁve Gal4 binding sites.
2046 BLAU ET AL. MOL.C ELL.B IOL.point mutations of Phe residues at positions 442, 473, 475, and
479. By the criterion of luciferase gene expression, this mutant
activator was about 100-fold weaker than wild-type VP16 and
approximately equivalent in strength to Gal4-Sp1 and Gal4-
Tat(1-48) (Fig. 2). In contrast to wild-type VP16, Gal4-SW6
resembled Gal4-Sp1 in stimulating transcription, which elon-
gated poorly as manifested by the sharp drop in polymerase
density between the 59 and 39 ends of the gene.
To test whether the nuclear run-on results with the pGal5-
myc luciferase template applied to a different promoter, we
transfected pGal5-HIV2 CAT into 293 cells with an expression
vector for Gal4(1-147), Gal4-VP16, or Gal4-SW6. Nuclear run-on
analysis (Fig. 3) showed that Gal4-VP16 stimulated transcrip-
tion that elongated with high efﬁciency, whereas transcription
activated by Gal4(1-147) or Gal4-SW6 elongated poorly. Gal4-
VP16 and Gal4-SW6 stimulated the 59 polymerase density
relative to Gal4(1-147) by ﬁve- and twofold, respectively, in
this experiment after normalization to a cotransfected VA
gene (data not shown). In all cases, read-around transcription
detected by the upstream probe G was low relative to tran-
scription downstream of the HIV-2 start site. We conclude that
the differences in elongation efﬁciency between different acti-
vators apply to two unrelated reporter genes. In summary, the
nuclear run-on analysis showed that some activators stimulate
elongation—the steps in transcription which occur after initi-
ation—while others do not and that these differences are not
related to the amounts of transcription that they stimulate.
RNase protection assay for the efﬁciency of transcriptional
elongation. To test whether the nuclear run-on results were
supported by an independent method, we used an RNase pro-
tection assay to analyze pGal5-HIV2 CAT transcripts activated
by Gal4-VP16 and -SW6. This assay (outlined in Fig. 4C) is
based on the observation that prematurely terminated HIV
RNAs are stable (31, 34). The TM RNase protection bands
represent a diffuse set of RNAs with 39 ends in the HIV-2 TAR
sequence, which acts as a terminator and/or stabilizer of ter-
minated transcripts (66). The RT RNase protection product
represents transcripts which initiate correctly and extend be-
yond position 1165. The weak bands marked RA in Fig. 4A
correspond to RNAs which either read around the plasmid or
initiate upstream of position 11. (Two read-around bands
were observed because of cleavage at a 2-base mismatch with
the probe just downstream of the TATA box.) We measured
the amounts of RT and TM products by densitometry and
expressed the efﬁciency of elongation as the ratio of RT to
total transcription (RT plus TM) after compensation for the
lower number of radioactive U residues protected by the
shorter TM transcripts. This value is useful for comparing
efﬁciencies of elongation but overestimates the absolute efﬁ-
ciency because termination sometimes occurs downstream of
position 1165, particularly with activators like Sp1 and SW6
(Fig. 2 and 3).
For Fig. 4, transcription of pGal5-HIV2 CAT was activated
by Gal4-VP16 and Gal4-SW6, which were expressed at equal
levels as demonstrated by Western blot (immunoblot) and gel
mobility shift analyses (data not shown). Transcripts were an-
alyzed with two RNase protection probes which differ at their
39 ends as shown in Fig. 4C. The shift in the positions of all of
the TM bands with probe 2 relative to those with probe 1 shows
that these RNase protection products are not the products of
random degradation during RNA isolation but rather corre-
spond to genuine 39 ends. Lanes 3 and 4 in Fig. 4A were
exposed threefold longer than lanes 1 and 2. Gal4-VP16-stim-
ulated transcription had an RT/(RT 1 TM) ratio of 62%,
versus 9% for Gal4-SW6. These results are in agreement with
those of the nuclear run-on experiment (Fig. 3) and conﬁrm
that the wild-type VP16 activation domain stimulates more
efﬁcient transcriptional elongation than the SW6 mutant.
We investigated the effect of the number of activator binding
sites on elongation efﬁciency. HIV-2 CAT reporters with either
one or ﬁve Gal4 binding sites were transfected into 293 cells
with the Gal4-VP16 expression vector. Transcripts were ana-
lyzed by RNase protection with probe 1 (Fig. 4A, lanes 6 and
7) and quantiﬁed (Fig. 4B, right panel). The elongation efﬁ-
ciency [RT/(RT 1 TM)] was 4.5-fold greater (58 versus 13%)
with ﬁve binding sites than with only one. In subsequent ex-
periments we used the ﬁve-site reporter, which was previously
FIG. 3. Gal4-VP16 stimulates more efﬁcient elongation than Gal4-SW6. Nuclear runon analysis (as in Fig. 2) of pGal5-HIV2 CAT in transfected 293 cells activated
by Gal4(1-147), -VP16, or -SW6 is shown. Autoradiograms were exposed for 10, 2, and 10 days, respectively. 53GAL, ﬁve Gal4 binding sites.
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vator (4).
Two classes of activators differ in their abilities to stimulate
transcriptional elongation. The RNase protection assay was
used to analyze a panel of activation domains (Fig. 1) for
stimulation of overall RNA synthesis and elongation efﬁciency
[RT/(RT 1 TM)]. Transcription with the Gal4(1-147) or
Gal4(1-94) DNA binding domains alone (Fig. 5A, lanes 6, 7, 9,
and 10 [lanes 9 and 10 show a four-times-longer exposure])
elongated poorly, as indicated by the relatively low percent
RT/(RT 1 TM) values (Fig. 5B). Expression of these DNA
binding domains did not stimulate transcription (relative to a
cotransfected VA control) above that observed for empty vec-
tor (2a). Gal4-SW6, Gal4-Sp1, and Gal4-CTF all clearly stim-
ulated RNA synthesis relative to Gal4(1-147) (Fig. 5A; com-
pare lanes 2 to 4 with lanes 6 and 7), but the efﬁciency of
elongation remained low. The results suggest that these acti-
vators stimulate initiation of transcription but not elongation.
We refer to this class of activators as type I.
In contrast to type I activators, Gal4-VP16, Gal4-E2F1, and
FIG. 4. RNase protection assay for transcriptional elongation through HIV-2
TAR. (A) Lanes 1 to 5, RNase protection of pGal5-HIV2 CAT transcripts
activated by Gal4-VP16 or Gal4-SW6. RNA from transfected 293 cells was
analyzed with probes 1 and 2 (see panel C). Size markers (M) are 180, 160, 148,
123, 110, 90, 76, and 67 bases. Read-around (RA), RT, and TM transcripts are
marked. Lanes 3 and 4 were exposed three times longer than lanes 1 and 2. Lanes
6 and 7, RNase protection of pGal5- and pGal1-HIV2 CAT transcripts with
probe 1. Lane 7 was exposed three times longer than lane 6. (B) Percent RT/(RT
1 TM) values determined by densitometry of the gels in panel A after correction
for the U content of the RT and TM bands. (C) RNase protection strategy.
Probes 1 and 2 were made from the pVZ HIV-2 template (73) cleaved with
EcoRI and AciI, respectively. Probe 1 extends to position 232 before its se-
quence diverges; probe 2 extends to position 112. 53GAL and 13GAL, ﬁve
Gal4 binding sites and one Gal4 binding site, respectively.
FIG. 5. Production of RT and TM transcripts by seven chimeric Gal4 acti-
vators. (A) RNase protection of pGal5-HIV2 CAT (probe 1 [Fig. 4C]) and VA1
(VA) transcripts. Lanes 8 to 10 are identical to lanes 5 to 7, respectively, except
that they were exposed four times longer. Lanes 11 and 12 are from an inde-
pendent experiment. RT and TM transcripts are marked. (B) The RNase pro-
tection products in the gel in panel A were quantiﬁed by densitometry, and
percent RT/(RT 1 TM) values were calculated as for Fig. 4B.
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ratio (Fig. 5) characteristic of efﬁcient elongation. Gal4-Tat(1-
48)-activated transcripts also elongated relatively efﬁciently,
but the amount of RNA synthesis was low relative to that with
VP16, E2F1, and p53 (Fig. 5A, lane 5, and a longer exposure
in lane 8). A strong effect of this activator on elongation was
more obvious when Sp1 was also present (see Fig. 9). In ad-
dition to affecting the RT/TM ratio, these activators shifted the
positions of the 39 ends of TM products towards the 39 end of
TAR (Fig. 5A; compare lanes 1, 8, 11, and 12 with lanes 2 to
4). We call the class of activators which stimulate efﬁcient
elongation type II.
In summary, the RNase protection data reinforce and ex-
tend the conclusions of the run-on experiments of Fig. 2 and 3.
Together these experiments distinguish two functional classes
of activator: type II activators stimulate elongation; type I
activators do not.
Only type I activators synergize with Tat. Southgate and
Green (62) showed that promoter-bound activators differ in
their responses to HIV Tat bound to nascent TAR RNA. They
found that Gal4-Sp1 synergized with Tat, whereas Gal4-VP16
did not. We have extended these results by using the Tat
cooperation assay to investigate our panel of activators (Fig.
1). HeLa cells were transfected with the pGal5-HIV2 CAT
reporter, expression vectors for Gal4 fusion proteins, and ei-
ther a Tat expression plasmid or an empty vector. CAT activity
in the presence of Tat was divided by activity in the absence of
Tat after normalization for transfection efﬁciency with an
RSV-luciferase reference gene. The results are plotted in Fig.
6. The type I activators Gal4-Sp1, -SW6, and -CTF synergized
strongly (92- to 114-fold) with Tat. In contrast, Tat had only a
two- to ﬁvefold effect in the presence of the type II activators
Gal4-Tat(1-48), -VP16, -p53, and -E2F1. In the absence of Tat,
type I activators stimulated 200- to 400-fold less CAT expres-
sion than the strong type II activators, Gal4-p53, -E2F1, and
-VP16, whereas in the presence of Tat, they were only about
5-fold weaker. In each case, the combined effect of Tat plus the
type I activator was far greater than the product of stimulation
by either factor alone.
Tat cooperation with the type I and II activators Gal4-SW6
and -VP16, respectively, was also examined by RNase protec-
tion (Fig. 7). Tat had a signiﬁcant effect on the efﬁciency of
elongation in the presence of Gal4-SW6 (Fig. 7; compare lanes
1 and 2) but little effect in the presence of Gal4-VP16 (Fig. 7,
lanes 3 and 4). Lanes 1 and 2 in Fig. 7 were exposed six times
longer than lanes 3 and 4.
In summary, the Tat cooperation assay precisely distin-
guishes between type I and type II activators. This assay there-
fore provides independent conﬁrmation of the conclusion
based on studies of elongation efﬁciency (Fig. 2 to 5) that there
are two functionally distinct classes of activators.
Type II activators differ in their abilities to cooperate with
Sp1. We also used an Sp1 cooperation assay in our attempts to
distinguish the functional properties of the activation domains
shown in Fig. 1. Southgate and Green (62) previously used this
assay to show that Gal4-Tat(1-48), but not Gal4-VP16, syner-
gizes with Sp1. CAT expression in transfected 293 cells was
measured for two pairs of reporter genes which differ only by
four tandem Sp1 sites inserted next to the TATA box (Fig. 8).
The CAT activity in the presence of Sp1 sites was divided by
the activity in the absence of Sp1 sites, and the fold activation
was plotted. The two pairs of reporters were pGal5-HIV2 CAT
with pGal5-Sp4-HIV2 CAT (Fig. 8A) and pGal5-E1b CAT with
pGal5-Sp4-E1b CAT (Fig. 8B). The latter pair of plasmids does
not contain any obvious terminator element analogous to the
HIV-2 TAR sequence. The two pairs of reporter genes be-
haved identically in response to different Gal4 activators. A
1.5- to 3-fold effect of Sp1 sites on stimulation of CAT expres-
sion was observed with type I Gal4 activators. On the other
hand, there were signiﬁcant differences among type II activa-
tors in their abilities to cooperate with Sp1. Gal4-Tat(1-48)
plus Sp1 activated 15- to 40-fold better than Gal4-Tat(1-48)
alone. This cooperation of Sp1 with Gal4-Tat(1-48) was slight-
ly more than multiplicative. On the other hand, Sp1 enhanced
transcription only 1.5- to 3-fold in the context of bound Gal4-
p53, -E2F1, or -VP16. The Sp1 cooperation assay therefore
distinguishes two subclasses of type II activator: type IIA, rep-
resented by Gal4-Tat(1-48), synergizes with Sp1; type IIB, rep-
resented by Gal4-p53, -E2F1, and VP16, does not synergize.
RNase protection (Fig. 9) showed that Gal4-Tat(1-48), like
FIG. 6. Synergy between HIV-1 Tat and type I but not type II activators. HeLa cells were transfected with pGal5-HIV2 CAT, RSV-luciferase, and various Gal4
expression vectors plus pSV-HIV1-tat or empty PECE vector. CAT expression was determined relative to luciferase activity, and the fold induction by Tat was
determined. Average values and standard deviations for at least three experiments for each activator are plotted.
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from the pGal5-Sp4-HIV2 CAT gene compared with Gal4(1-
147), Gal4-SW6, or Gal4-Sp1. Lanes 1 to 3 in Fig. 9A were
exposed 3.5 times longer than lanes 4 and 5. Transcription
activated by Gal4-Tat(1-48) elongated as efﬁciently as that
stimulated by Gal4-VP16 (Fig. 9B). The data in Fig. 9 there-
fore conﬁrm the strong effect of Gal4-Tat(1-48) on elongation
which was observed in the absence of a cooperating factor (Fig.
2 and 5) when the overall amount of transcription was much
less.
Activators that stimulate elongation bind to TFIIH. The
functional difference between type I and type II activators
might be explained by the nature of the GTFs that they contact
in the preinitiation complex. For example, the Tat, VP16, E2F1,
and p53 activation domains may stimulate elongation by tar-
geting a common component of the transcription machinery
which is not contacted by Sp1, CTF, or SW6. With the excep-
tion of SW6, all of these activators have been reported to
interact with TFIID subunits (7, 11, 17, 19, 22, 32, 67, 71). In
addition, VP16 and CTF also bind TFIIB (35, 44). There are
no obvious correlations between the reported contacts with
TFIID or TFIIB and the classiﬁcation of an activator as type I
or type II. On the other hand, we have noted that the type II
acidic activators VP16, p53, and E2F1 all interact with TFIIH,
whereas a VP16 mutant similar to SW6 cannot (50a, 72). To
test whether this correlation extended to the other activation
domains shown in Fig. 1, we examined whether TFIIH could
interact with Tat, Sp1, CTF, and SW6. HeLa cell extracts were
chromatographed on columns containing immobilized activa-
tion domains fused to GST, and proteins retained on the col-
umns were eluted and analyzed by Western blotting with an-
tibodies against subunits of TFIIH.
Like VP16, both full-length HIV-1 Tat (positions 1 to 72)
and its 48-amino-acid N-terminal activation domain bound the
TFIIH in HeLa extracts as judged by Western blotting with
antibody against the p62 subunit of TFIIH (Fig. 10A, lanes 5
and 6). This interaction between Tat and TFIIH is likely to be
direct because the immobilized Tat activation domain also
bound to the
35S-labelled p62 subunit of TFIIH when it was
made by translation in a rabbit reticulocyte lysate (70a). West-
ern blotting did not reveal any binding of TFIIB, TFIIE, or
TFIIF to Tat in these experiments, although Tat did bind
TFIID as detected by anti-TBP antibody, in agreement with
published results (32) (data not shown). In contrast to Tat,
GST-Sp1A, -Sp1B, -CTF, and -SW6 did not bind any more
TFIIH than the GST control resin (Fig. 10A, lanes 3, 8, and 9;
Fig. 10B, lane 6). In addition, the experiment of Fig. 10B shows
that the form of TFIIH retained by the Tat and VP16 activa-
tion domains contains the p40
MO15 protein kinase subunit.
These results therefore extend our observations that type II
activators bind TFIIH and show, in addition, that type I acti-
vators do not bind TFIIH.
DISCUSSION
Three classes of activators differ in their abilities to affect
initiation and postinitiation steps in transcription. In this pa-
per, we have distinguished between activation domains on the
basis of whether they stimulate the postinitiation (elongation)
stage in pol II transcription. Three independent lines of evi-
dence were used to make this distinction: (i) polymerase dis-
tribution along the gene determined by nuclear run-on analy-
sis, (ii) production of truncated transcripts detected by RNase
protection, and (iii) synergy with other activators assayed by
reporter gene activity.
The type I activators Sp1, CTF, and the VP16 mutant SW6
gave rise to a skewed polymerase distribution with a sharp drop
in density immediately downstream from the 59 end (Fig. 2 and
3 and data not shown). These activators gave rise to abundant
truncated RNAs (Fig. 5), indicating that they stimulated initi-
ation of transcription. Type I activators synergized strongly
with HIV Tat but not with Sp1 (Fig. 6 and 8). In contrast, type
II activators gave rise to a uniform distribution of polymerases
along the gene (Fig. 2 and 3) and produced relatively few
truncated transcripts (Fig. 5). There is, however, functional
heterogeneity among type II activators. Type IIA has only one
identiﬁed representative, Gal4-Tat(1-48), a weak activator that
synergized well with the type I activator Sp1 (Fig. 8). We think
it likely that there are as-yet-unidentiﬁed cellular type IIA
DNA binding factors similar to Gal4-Tat(1-48). One possible
candidate is PBP, an ATF/CREB family member which acti-
vates promoter clearance but not preinitiation complex assem-
bly or open complex formation (49). Type IIB activators, rep-
resented by Gal4-p53, -E2F1, and -VP16, are strong activators
that do not synergize with Sp1 (Fig. 8). To explain these dif-
FIG. 7. Tat stimulates elongation with Gal4-SW6 but not Gal4-VP16. RNase
protection of pGal5-HIV2 CAT transcripts from HeLa cells transfected as for
Fig. 6 with the Gal4-VP16 or -SW6 expression vector without or with Tat is
shown. RNase protection of the cotransfected pSp65-VA1 transcripts demon-
strated equal transfection efﬁciencies (not shown).
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stimulate initiation but not elongation, type IIA activators
stimulate predominantly elongation, and type IIB activators
strongly stimulate both initiation and elongation. This model
for the three functional classes of activators is summarized in
Fig. 11. Further analysis may reveal more functional sub-
classes. For example, different type I activators could stimulate
different steps in initiation by contacting different sets of GTFs.
We observed production of truncated RNAs (Fig. 5) and
promoter-proximal pausing by pol II (Fig. 2) (38, 64) when
examining nonactivated transcription or transcription activated
by type I but not type II activators. In contrast, a recent nuclear
run-on analysis with various Gal4-fusion proteins led to the
conclusion that all activation domains stimulated transcription
which pauses in the promoter-proximal region, although paus-
ing was reduced in the presence of VP16 (37). In order to
reveal functional differences between activators when reporter
genes with multiple binding sites are used, it is probably nec-
essary for the activators to be saturating so as to maximize
synergy between multiple copies of the same activator. When
the occupancy of the binding sites is low, most activators may
predominantly stimulate initiation. Our experiments may have
demonstrated more clear-cut differences between activation
domains than observed previously (37) because our reporter
genes (which had ﬁve, rather than three, Gal4 binding sites)
were more fully saturated with each activator. In support of
this explanation, transcription activated by Gal4-VP16 from a
single-site reporter is less processive than that from a ﬁve-site
reporter (Fig. 4A). This effect of binding site number on the
elongation efﬁciency of Gal4-VP16-activated transcription pre-
sumably contributes in part to the synergistic activation of gene
expression by multiple copies of this activator (4).
Mutation of VP16 switches it from type II to type I. Our
experiments suggest that type IIB activators like VP16 have a
FIG. 8. Sp1 synergizes with Gal4-Tat(1-48) but not with other activators. (A) 293 cells were transfected with expression vectors for various Gal4 activators and either
pGal5-HIV2 CAT or pGal5-Sp4-HIV2 CAT. CAT activity was normalized to the activity of cotransfected RSV-luciferase, and the fold induction by Sp1 was plotted.
The data shown are average values and standard deviations based on results from three independent experiments. (B) Experiments were conducted as for panel A
except that the reporter was pGal5-E1b CAT or pGal5-Sp4-E1b CAT. Fold induction by Sp1 is plotted. The data are from three independent experiments. 53GAL,
ﬁve Gal4 binding sites; Sp4, four Sp1 binding sites.
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tion and at least one postinitiation event. The SW6 mutant of
VP16 has four substitutions of Phe residues at positions 442,
473, 475, and 479. Gal4-SW6 is a much weaker activator than
Gal4-VP16 as assayed by luciferase and CAT reporter gene
expression (Fig. 2) (68), but it does not behave like a weak type
II activator such as Gal4-Tat(1-48). Instead, it behaves like a
type I activator by the criteria of the nuclear run-on assay (Fig.
2 and 3), the RNase protection assay (Fig. 4 and 5), and
synergy with other activators (Fig. 6 to 8). In fact, SW6 was
functionally indistinguishable from the CTF and Sp1 activation
domains. The four mutations in SW6 therefore result in a
qualitative, as well as a quantitative, change in transcription,
effectively converting the VP16 activation domain from type
IIB to type I. The initiation and elongation functions of a type
IIB activator are therefore at least partially separable by ge-
netic means.
The behavior of SW6 underscores the fact that there is no
simple relationship between amino acid composition and func-
tion. The three type IIB activators VP16, p53, and E2F1 all
have acidic activation domains, but Gal4-E1a(121-222), which
also belongs to this class (2a, 74), is not highly acidic. SW6 is as
acidic as VP16 yet behaves like the type I proline- and glu-
tamine-rich activation domains of CTF and Sp1.
Implications for the function of HIV Tat. The ﬁrst activator
shown to stimulate pol II elongation was HIV Tat, but its
mechanism of action remains a matter for speculation (28).
The binding of Tat to nascent RNA, rather than DNA, sug-
gested that it may act directly on the elongating ternary com-
plex as an antitermination factor similar to the phage lambda
N protein (21). This idea was challenged by the observation
that Tat could also stimulate transcription after binding to
DNA when it was fused to the DNA binding domain of c-Jun
or Gal4 (2, 29, 62). It was not determined whether activation by
Jun-Tat or Gal4-Tat in these experiments occurred by stimu-
lation of elongation or initiation. It was therefore possible that
FIG. 9. Gal4-Tat(1-48) synergizes with Sp1 by istimulating transcriptional
elongation. (A) 293 cells were transfected with pGal5-Sp4-HIV2 CAT, RSV-
luciferase, pSp65-VA1, and Gal4 expression plasmids. HIV-2 transcripts were
analyzed by RNase protection as for Fig. 5A. Lanes 1 to 3 were exposed 3.5 times
longer than lanes 4 and 5, as indicated. RNase protection demonstrated equal
expression of VA1 transcripts (not shown). 53GAL, ﬁve Gal4 binding sites; Sp4,
four Sp1 binding sites. (B) Percent RT/(RT 1 TM) determined by densitometry
of the autoradiogram in panel A. (C) Relative CAT activity normalized to
RSV-luciferase activity for each Gal4 activator.
FIG. 10. Type II but not type I activation domains bind to TFIIH. (A) HeLa
whole-cell extracts (800 ml) were chromatographed on microcolumns containing
various immobilized GST fusion proteins. Bound proteins were eluted in 160 ml
of buffer containing 1 M NaCl, and 20 ml was analyzed by immunoblotting with
monoclonal antibody 3c9 against the p62 subunit of TFIIH. HeLa cell extract (10
ml) was run as a marker in lane 1. No signiﬁcant amount of p62 was detected
when the GST, GST-Sp1A, GST-Sp1B, and GST-CTF columns were subse-
quently eluted with SDS (data not shown). (B) HeLa cell nuclear extracts were
chromatographed on 0.6-ml columns containing various immobilized GST fusion
proteins, and the bound proteins were eluted with 0.6 M KCl and analyzed by
immunoblotting with monoclonal anti-p62 and anti p40
MO15 antibodies.
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promoter by DNA binding or to the ternary complex by RNA
binding. Only Tat activation via TAR RNA, for example, is
likely to involve cellular TAR binding factors (28).
Our results (Fig. 2, 5, and 9) show that Gal4-Tat(1-48)
bound to DNA operates in a way similar to Tat bound to TAR
RNA, that is, by stimulating transcriptional elongation by pol
II. The effect of Tat on elongation is therefore not peculiar to
its unusual mode of recruitment to the transcription complex.
The strong effect of Gal4-Tat(1-48) on elongation also shows
that stimulation of this step is not a trivial consequence of a
high initiation rate, since it is a very weak activator. Indeed, we
did not ﬁnd evidence for signiﬁcant stimulation of initiation by
Gal4-Tat(1-48) relative to the Gal4(1-147) DNA binding do-
main (Fig. 5A). There could be differences between the behav-
iors of Gal4-Tat(1-48) and Tat itself, however, since the latter
does stimulate initiation in some cases (39).
Gal4-Tat(1-48) strongly activated transcription from pGal5-
Sp4-E1b CAT (Fig. 8B) (30, 62), which does not contain a
known terminator. Our other results make it likely that Gal4-
Tat(1-48) activated this reporter gene by stimulating elonga-
tion. Postinitiation effects of activators therefore do not appear
to be limited to a subset of genes containing speciﬁc termina-
tors, consistent with the report that promoter-proximal paus-
ing is, in fact, a very general phenomenon (37).
Synergy between activators that stimulate initiation and
elongation. Sp1 was previously shown to synergize with Tat and
Gal4-Tat, while VP16 did not, but the reasons for this differ-
ence remained unclear (29, 30, 62). In one case, in which Tat
cooperation with VP16 was reported (16), the reporter plas-
mids contained multiple Sp1 sites which almost certainly con-
tributed to the effect observed. A second reported instance of
synergy between Gal4-VP16 and Sp1 was exceptional in that
Gal4-VP16 was bound downstream of the gene and activated
transcription only threefold (69). We have observed synergy
between Sp1 and Gal4-VP16 bound to a single Gal4 site but
not with ﬁve Gal4 binding sites (2a).
Our experiments suggest an explanation for why some com-
binations of activator synergize and others do not. When self-
cooperation between identical activators was maximized by
saturating the promoter, the only synergistic combinations we
observed were those involving type I and type IIA activators,
which affect initiation and elongation, respectively. Only Gal4-
Tat(1-48) (type IIA), and none of the type I or type IIB acti-
vators, synergized with Sp1 (type I) (Fig. 8). Conversely, only
the type I activators, Gal4-Sp1, -CTF, and -SW6, synergized
with Tat, while the type IIA and IIB activators, Gal4-Tat(1-48),
-VP16 -p53, and -E2F1, did not (Fig. 6). Synergy with Tat was
not inversely related to the activator strength as previously
proposed (62). Although Gal4-Tat(1-48) is a weak activator, it
does not synergize with Tat, while other weak activators (Gal4-
CTF, -Sp1, and -SW6) do synergize with Tat. In summary, the
only combinations of activators which synergized under our
conditions were those which stimulated two apparently distinct
rate-limiting steps in transcription: initiation and elongation.
This result is consistent with a model for synergy proposed by
Herschlag and Johnson (25).
Contributions of elongation and initiation to gene activa-
tion. Neither the nuclear run-on assay nor the RNase protec-
tion assay directly measures initiation rates; therefore, we can-
not accurately estimate the contribution of increased initiation
rate to the stimulation of gene expression. However, there is
no doubt that it plays an important role. The nuclear run-on
assay measures the density of preinitiated polymerases at the
59 end of the gene but does not distinguish between stalled and
actively elongating polymerases. Stalled polymerases resume
transcription in the run-on assay and produce high 59 run-on
signals even if little or no active initiation is occurring. Run-on
reactions therefore underestimate the stimulation of initiation
by activators. For this reason, the 5- to 10-fold enhancement of
59 polymerase density by Gal4-VP16 relative to Gal4(1-147)
(Fig. 2 and 3) is a minimum estimate of the effect on initiation.
Gal4-VP16 and other type II activators stimulated elongation
efﬁciency by about 10-fold relative to Gal4(1-147) and type I
activators (Fig. 2 and 3). Together the effects on initiation and
elongation account for most of the 200- to 300-fold stimulation
of CAT activity by Gal4-VP16 relative to Gal4(1-147).
In contrast to type IIB activators, the type I activators, Gal4-
Sp1, -CTF, and -SW6, stimulate only initiation, and the type
IIA activator, Gal4-Tat(1-48), stimulates only elongation. Type
I and type IIA activators stimulate similar levels of reporter
gene expression (Fig. 2) by two different mechanisms. Only in
combination with one another do they generate high levels of
gene expression comparable to that generated by type IIB
activators (Fig. 9C).
By stimulating elongation and suppressing promoter-proxi-
mal pausing, type II activators may indirectly permit higher
initiation rates by removing stalled polymerases which would
otherwise obstruct the start site. The Drosophila heat shock
factor, HSF, is believed to function in this way (45). This type
of effect could make an important contribution to the synergy
between type I and type IIA activators (Fig. 9) and may also
contribute to the high initiation rates associated with type IIB
activators such as VP16, E2F1, and p53. We suggest that the
reason that type IIB activators are stronger than other types is
precisely because they stimulate both initiation and elongation.
Further support for this idea could be provided by isolation of
a second type of mutant VP16 which, unlike SW6, behaves as
a type IIA activator that stimulates elongation but not initia-
tion.
A role for TFIIH in activation of transcription after initia-
tion? Several previous reports have identiﬁed functional dif-
ferences between certain type I and type II activators. Gal4-
Sp1 and Gal4-CTF activate transcription signiﬁcantly better
from promoter-proximal positions than from distal positions,
whereas Gal4-VP16 activates equally well from both positions
(56). Gal4-VP16 and -Sp1 also behave differently in their abil-
ities to activate various mRNA and small nuclear RNA pro-
moters (8). Additionally, transcription that is activated by Gal4-
FIG. 11. Model for three functional classes of activation domains. Type I
does not bind TFIIH and activates initiation by nonprocessive transcription
complexes (open circles). Types IIA and IIB bind TFIIH (H) and cause elon-
gation to be processive (ﬁlled circles). Tat synergizes well with all type I activa-
tors but not with type IIA or IIB. Sp1, a type I activator, synergizes with
Gal4-Tat(1-48) (type IIA) but not with type IIB or other type I activators.
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whereas Gal4-CTF and -Sp1 are largely unresponsive (53). An
additional functional distinction was found in an elegant study
showing that activation by Gal4-VP16 is inhibited by deletion
of the pol II CTD, whereas Sp1-activated transcription is un-
affected (15).
This last observation is particularly intriguing given the cor-
relation we observed between binding of TFIIH and stimula-
tion of elongation. Phosphorylation of the pol II CTD by
TFIIH could be involved in the stimulation of elongation by
type II activators. All of the type II activators that we have
identiﬁed bind TFIIH, whereas type I activators do not (Fig.
10). This correlation suggests that TFIIH may be involved in
activator-mediated stimulation of postinitiation events in tran-
scription. In several Drosophila genes, CTD phosphorylation is
correlated with stimulation of elongation by stalled poly-
merases near the start sites (50, 70). The binding of an activa-
tion domain to TFIIH could modulate the activity of the MO15
cyclin-dependent kinase associated with this GTF.
The binding of TFIIH to VP16 is severely reduced by the
mutations in SW6 (72) (Fig. 10B), which also abolish the ability
of this activator to stimulate elongation. The altered properties
of the SW6 mutant are consistent with the model that binding
to TFIIH is required for stimulation of elongation, but they do
not prove the case, since interactions with other factors, such
as TBP, are also affected (reference 27 and data not shown).
Reduced binding of SW6 to TBP may explain the reduced level
of initiation relative to that with wild-type VP16 apparent in
some of our experiments (Fig. 2 and 4). An elongation function
of TFIIH is also consistent with our observation that inhibitors
of TFIIH kinase, such as dichlororibofuranosylbenzimidazole
(DRB), also inhibit pol II elongation (74). Herrmann and Rice
(23) showed that Tat interacts with a CTD kinase other than
TFIIH (although of similar molecular weight) (24) which is
also inhibited by DRB. It is therefore possible that activators
interact with multiple CTD kinases in order to modulate tran-
scription.
On the basis of this evidence, we propose, as a working
model, that type II activators stimulate elongation, at least in
part, by recruiting and/or stimulating the TFIIH protein ki-
nase, which converts the polymerase from a nonprocessive to a
processive form (Fig. 11). In contrast, type I activators such as
Sp1, CTF, and the SW6 mutant of VP16 lack this capability
and stimulate only initiation by virtue of their interactions with
factors such as TFIID and TFIIB (11, 17, 35, 71).
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